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Abstract 
Macrovascular complications of diabetes, including diabetic cardiovascular disease (CVD), occur 
through a number of hyperglycaemia-induced mechanisms that include generation of oxidative stress, 
accumulation of advanced glycation end-products (AGE) and activation of protein kinase C (PKC). 
Cardiac oxidative stress is associated with increased cardiac fibrosis and hypertrophy, and reduced 
cardiac performance and contractility, leading to severe cardiac dysfunction and potentially fatal 
cardiac events. It occurs under conditions of excessive synthesis of reactive oxygen species (ROS). The 
ensuing activation of transcription factors such as nuclear factor-κB produces inflammation, fibrosis, 
hypertrophy and further oxidative stress, which itself causes DNA and membrane damage. This review 
summarises the mechanisms that generate ROS in the diabetic heart: mitochondrial electron leakage, 
activity of ROS-generating enzymes such as NADPH oxidase, xanthine oxidase and 12/15 lipoxygenase, 
uncoupling of nitric oxide synthase, accumulation of AGEs and activation of PKC. There is interaction 
between many of these ROS-generating pathways, with data from a range of published studies 
indicating that a common upstream pathway is the interaction of AGEs with their receptor (RAGE), 
which further promotes ROS synthesis. Therefore, agents targeted at decreasing ROS production have 
been investigated for prevention or treatment of diabetic CVD through reducing oxidative stress, and 
this review considers some of the studies carried out with anti-oxidant therapies and the feasibility of 
this approach for protecting against diabetic cardiomyopathy.  
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1. Introduction 
1.1 Chronic hyperglycaemia and cardiovascular disease 
Diabetes mellitus is a metabolic disorder where reduced insulin sensitivity and defective 
insulin secretion lead to hyperglycaemia through inadequate glucose storage and inappropriate 
glycogenolysis and gluconeogenesis. The global burden of diabetes and the threat posed by diabetes 
to human health has become very severe in recent years, mainly as a consequence of increased 
urbanisation, population ageing and changes in lifestyle that lead to increased body mass index (BMI) 
1,2. Global projections of diabetes in 2010 proposed that 439 million adults worldwide would have 
diabetes by 20303, but already 415 million adults have diabetes and this is predicted to increase to 642 
million by 20404.   
It is the long term microvascular and macrovascular complications of chronic hyperglycaemia 
that lead to mortality and morbidity in diabetes. The microvascular complications affect small blood 
vessels and include nephropathy, neuropathy and retinopathy, while the macrovascular complications 
comprise cardiovascular, cerebrovascular and peripheral artery diseases5. The current treatments for 
diabetes aim to control hyperglycaemia and prevent hyperglycaemia-induced tissue damage through 
lifestyle changes and pharmacological interventions6.  
The increased risk of cardiovascular disease (CVD) in diabetic patients was made evident by 
the Framingham7 and the MERIT8 clinical trials, which indicated that diabetic patients have a 2 to 4-
fold increased risk of CVD. Furthermore, diabetic patients have a 3-fold higher mortality rate than the 
non-diabetic population, highlighting that this condition is potentially fatal. Diabetic CVD encompasses 
a range of cardiovascular conditions, including diabetic cardiomyopathy9, coronary heart disease and 
congestive heart failure7. Oxidative stress is believed to be involved in the pathogenesis of all of these 
conditions10 and this review will focus primarily on the role of enhanced ROS production in the 
development of diabetic cardiomyopathy. 
 
1.2 Diabetic cardiomyopathy   
Diabetic cardiomyopathy was first described in 1972 in four diabetic patients who presented 
with heart failure11. It is a term used to distinguish between diabetes-associated cardiomyopathy, and 
cardiomyopathy that is associated with other co-morbidities such as hypertension or coronary artery 
disease9, and these co-morbidities can significantly affect a patient’s prognosis with diabetic 
cardiomyopathy12. In a study in which endomyocardial biopsies were taken from 16 diabetic patients 
it was determined that those subjects with symptomatic cardiac failure had the most significant 
myocardial changes and therefore the greatest structural and functional alterations13. The clinical 
features of diabetic cardiomyopathy include alterations in ventricular morphology such as concentric 
remodelling of the left ventricle leading to left ventricular hypertrophy, interstitial and perivascular 
fibrosis leading to reduced ventricular compliance, and diastolic dysfunction (Figure 1)14. These clinical 
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features manifest with symptoms that include shortness of breath, fatigue, weakness and ankle 
oedema. In addition, asymptomatic diabetic patients and individuals with pre-diabetes can also 
demonstrate mild changes in cardiac function, such as diastolic dysfunction12, 15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3. Reactive oxygen species and oxidative stress  
The term ROS encompasses free radical species, such as hydroxyl (OH.) and superoxide (O2.), 
and non-radical species such as hydrogen peroxide (H2O2). Historically, ROS generation was thought to 
be a form of pathological cellular stress, but the current consensus is that synthesis and degradation 
of ROS are physiological, homeostatic functions of many cells10,16. However, if ROS levels are not 
balanced through appropriate regulation of production and removal, oxidative stress may occur and 
the modifications of proteins, DNA and lipids by excess ROS is associated with diabetic 
complications10,16. It has recently been reported that induction of diabetes in guinea pigs through 
streptozotocin (STZ) treatment led to abnormal cardiac contraction and relaxation, and isolated 
cardiomyocytes exhibited increased oxidative stress17. Furthermore, even a pre-diabetic state in rats, 
through administration of a single low dose of STZ, was associated with diastolic dysfunction that was 
accompanied by increased left ventricular mass and wall thickness 15. Sub-sarcolemmal mitochondrial 
Figure 1. Clinical features and symptoms of diabetic cardiomyopathy.  
The clinical features of diabetic cardiomyopathy include structural changes to the left ventricle 
including ventricular hypertrophy, fibrosis, reduced ventricular compliance and diastolic 
dysfunction. The symptoms include chest pain, elevated blood pressure, shortness of breath on 
exertion and ankle oedema.  
 
Ankle oedema 
 
Alterations in cardiac 
morphology, raised blood 
pressure, chest pain 
 
Shortness of breath, 
particularly on exertion 
 
Constitutional symptoms: 
Weakness 
Fatigue  
 
~ 5 ~ 
 
H2O2 production in these pre-diabetic animals was elevated, again supporting a role for 
hyperglycaemia-induced cardiac dysfunction being mediated through oxidative stress.  
This review summarises the pathways in diabetes that generate ROS and cause oxidative stress 
in the heart, illustrates the damaging effects of oxidative stress and discusses the potential role of anti-
oxidant therapy as treatment for diabetic CVD, with a particular focus on diabetic cardiomyopathy.  
 
2. Sources of ROS in the diabetic heart 
In diabetes, insufficient insulin-dependent glucose uptake into fat and skeletal muscle and 
inappropriate glycogenolysis and gluconeogenesis leads to elevated plasma glucose levels, and this 
hyperglycaemia can promote elevations in ROS synthesis in the heart18. Figure 2 shows the pathways 
that generate ROS within the diabetic heart: leakage of the mitochondrial electron transport chain 
(ETC), increased activity of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), 
xanthine oxidase and 12/15 lipoxygenase (LOX) enzymes, uncoupling of nitric oxide synthase (NOS), 
activation of protein kinase C (PKC) and the interaction of advanced glycation end-products (AGE) with 
the receptor for AGE (RAGE)10. There may also be interactions between these pathways in the diabetic 
state, enabling a profound overproduction of ROS and increased oxidative stress, which can result in 
diabetic CVD. Specifically, the activation of RAGE in diabetes has been implicated as an upstream 
common pathway that promotes ROS generation through the activity of NADPH oxidase and increased 
mitochondrial activity.  
 
 
Figure 2. Superoxide (O2.) generating pathways.  
Under conditions of hyperglycaemia the following intracellular changes occur that result in 
increased O2. generation: enzymes (NADPH oxidase, xanthine oxidase, 12/15 lipoxygenase, PKC) are 
activated, advanced glycation end-products (AGEs) are generated, increased flux through the 
mitochondrial electron transport chain (ETC) causes formation of the mitochondrial permeability 
transition pore (MPTP), and nitric oxide synthase (NOS) is uncoupled from nitric oxide production.  
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2.1. The mitochondrial electron transport chain 
The mitochondria are intracellular organelles responsible for oxidative metabolism of glucose 
to provide energy through ATP synthesis. In the hyperglycaemic state the mitochondria generate 
excessive O2. as a consequence of increased oxidative metabolic flux.  
 
2.1.1 ROS generation via mitochondrial electron leakage 
During physiological oxidative phosphorylation, there is transfer of electrons into the ETC 
located on the inner mitochondrial membrane. A series of complexes embedded in the membrane 
utilise the energy from the electrons to pump hydrogen ions (H+) into the inter-membrane space, 
generating an electrochemical gradient between the inter-membrane space and the mitochondrial 
matrix and this is used by ATP synthase to generate ATP. The transfer of electrons into the ETC is 
directly related to the concentration of intracellular glucose so under conditions of hyperglycaemia the 
ETC will become saturated, forcing the electrons to be transferred to molecular oxygen, generating O2. 
within the mitochondria of these cells19 (Figure 3). The O2. that is generated can be converted to H2O2 
by superoxide dismutase (SOD) and then de-toxified to water by the anti-oxidant enzymes glutathione 
peroxidase and catalase. However, H2O2 can also decompose to generate highly damaging OH. radicals 
and there is further insult to the ETC through the formation of the mitochondrial permeability 
transition pore (MPTP). Under conditions of oxidative stress, a pore opens on the inner mitochondrial 
membrane that allows the passage of H+ down the electrochemical gradient into the mitochondrial 
matrix without ATP generation. This is known as uncoupling of the ETC and it can lead to further O2. 
generation, swelling of the mitochondrial matrix and leakage of cytochrome C, a component of the 
ETC, into the cytosol causing apoptosis20 (Figure 3).  
The mitochondria themselves may be susceptible to the ROS they produce, causing local 
damage to mitochondrial DNA and membranes, further impairing the normal activity of the ETC and 
therefore generating more ROS through a positive feedback mechanism21. Increased mitochondrial O2. 
production has been observed in a canine model of heart failure, where there was a 2-fold reduction 
in the activity of complex 1 of the ETC that resulted in a 2.8-fold increase in O2. production, as measured 
using electron spin resonance spectroscopy (ESR)22. These observations are consistent with the cardiac 
ETC generating ROS to impair heart function, most likely through lipid modification within the heart 
since there was a significant increase in 4-hydroxy-2-nonenal (4-HNE), a byproduct of ROS-induced 
lipid peroxidation, in myocardial sections retrieved from the dogs with heart failure. 
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Endogenously produced free radicals may not be generated in sufficiently high concentrations 
or they may have such short half-lives that they are undetectable by standard ESR, so spin traps can 
be utilised to detect free radicals. Spin traps, such as 5,5-dimethyl-pyrroline N-oxide (DMPO), bind to 
the free radicals and form stable adducts that can then be detected using ESR23. In one study in which 
ETC-derived OH. radicals were measured using ESR and spin trapping with DMPO in cardiac sub-
mitochondrial particles it was found that administration of SOD and antimycin, an inhibitor of the ETC 
which collapses the H+ gradient, produced more OH. adducts, thus providing further evidence for the 
role of the ETC in ROS generation in cardiac pathology24. Further experimentation showed a 2.9-fold 
increase in the formation of 8-hydroxydeoxyguanosine (8-OH-dG), an oxidised form of the 
deoxyguanosine DNA nucleoside, on addition of the citric acid cycle intermediate succinate, and a 3.4-
fold increase of 8-OH-dG on addition of succinate and antimycin24. These results suggest that 
Figure 3. Superoxide production via the electron transport chain 
Under conditions of hyperglycaemia increased glucose metabolism results in enhanced flux 
through the citric acid cycle, which increases ATP synthesis, but also leads to electron leakage that 
results in elevations in formation of superoxide (O2.). The schematic shows generation of ATP and 
O2. from the electron transport chain and the position of the mitochondrial permeability transition 
pore.  
Nicotinamide adenine dinucleotide (NAD/NADH); flavin adenine dinucleotide (FAD/FADH2); 
electron (e-); cytochrome c (cyt c); hydrogen ion (H+); Complexes I, II, III and IV of the ETC (I, II, III, 
IV); superoxide dismutase (SOD); hydrogen peroxide (H2O2); hydroxyl (OH.). 
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mitochondrial DNA was oxidised by the OH. generated, but there was no evidence of a causal 
relationship in this study.    
 
2.1.2 ROS generation via alterations in the mitochondrial hydrogen ion electrochemical gradient   
Antimycin mediates uncoupling of the ETC via dissipation of the H+ electrochemical gradient 
and this has been associated with an increase in ROS synthesis24. However, other studies have shown 
that administration of uncoupling agents that collapse the H+ gradient to aortic endothelial cells, under 
hyperglycaemic conditions, caused a reduction in ROS generation to levels not statistically different 
from those produced by these cells when incubated with a physiological glucose concentration (5mM 
glucose)18. A recent review provided some insight into the discrepancy observed between these two 
studies. It has been suggested that mild uncoupling of the ETC leads to a reduction in ETC-mediated 
ROS accumulation by reducing the driving force of H+ from the intermembrane space into the matrix 
of the mitochondria. However, profound uncoupling of the ETC will cause full dissipation of the 
electrochemical gradient and generate more ROS to produce oxidative stress25. Therefore, the 
inconsistency between these studies may reflect differences in the extent of mitochondrial ETC 
uncoupling18,24. Furthermore, disparities may be attributed to differences in experimental protocol. 
For example, one study used intact healthy bovine aortic endothelial cells in the hyperglycaemic state18 
whereas the other used bovine sub-mitochondrial particles under normoglycaemic conditions24. 
Nevertheless, these studies provide further support for the role of mitochondria in the generation of 
oxidative stress, placing emphasis on the involvement of the H+ electrochemical gradient.  
 
2.2. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases 
NADPH oxidases, phagocytic ROS-generating enzymes, are comprised of cytochrome b558, 
which is a membrane spanning component, and cytosolic components (Figure 4). Cytochrome b558 is 
composed of the phagocytic oxidases p22phox and gp91phox, and the cytosolic components comprise 
rac, p47phox, p67phox and p40phox10. NADPH oxidases have a physiological function to generate ROS 
as a means of cellular protection from pathogens. Individuals with chronic granulomatous disease have 
mutations in the phox proteins that constitute NADPH oxidase and they characteristically suffer from 
recurrent fungal and bacterial infections as well as inflammatory disorders such as inflammatory bowel 
disease, highlighting the protective role of NADPH oxidases in host defence26.  
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2.2.1 NADPH-dependent superoxide production   
The cytosolic components of NADPH oxidase interact with cytochrome b558 at the membrane 
to produce an activated form of NADPH oxidase that catalyses the transfer of electrons to molecular 
oxygen, generating O2.10 (Figure 4). NADPH oxidase-dependent O2. production is reported to be 
significantly elevated in guinea pig left ventricular hypertrophy (LVH) tissue homogenates, and there 
was also an increase in expression of the NADPH oxidase component gp91phox, also known as NOX2, 
in the cardiomyocytes of the LVH guinea pigs27. This indicates that NOX2 is upregulated in the 
myocardium of the LVH guinea pigs, which may account for the rise in NADPH oxidase-dependent O2. 
production. NOX2 has also been implicated in the induction of cardiac hypertrophy by the 
vasoconstrictive peptide angiotensin II through observations that small interference RNA (siRNA)-
induced knock down of NOX2 expression in cardiomyocytes abolished both angiotensin II-induced O2. 
synthesis and cardiomyocyte hypertrophy28. Other specific NADPH oxidase isoforms, with various 
cytochrome subunits (NOX), have been further investigated. NOX1 and NOX3 are not expressed by 
mouse heart29 but studies have been performed to identify the role of the NOX4 isoform that is mainly 
expressed in the mitochondria of cardiomyocytes. Cardiac-specific NOX4 knockout mice (c-Nox4-/-) 
showed a 40% reduction in O2. synthesis in response to pressure overload, indicating that NOX4 is 
important for O2. production by the myocardium29. Conversely, cardiac-specific NOX4 over-expression 
was associated with more pronounced effects of pressure overload, with increased cardiac dysfunction 
Figure 4. Components of NADPH oxidase  
NADPH oxidases are enzymes consisting of multiple phox (phagocytic oxidase) subunits. Transfer 
of electrons from NADPH to oxygen generates superoxide (O2.), to provide cellular protection 
against pathogens, and NADP+ and H+ are also produced in the process. Diabetes is associated with 
increased cardiac NADPH oxidase-dependent O2. generation, leading to the production of oxidative 
stress.  
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and elevated apoptosis of cardiac cells, supporting a role for this O2.-generating enzyme in oxidative 
stress in the failing heart29.  
The role of rac1, a cytosolic component of many NADPH oxidase isoforms (Figure 4), in the 
pathogenesis of diabetic cardiomyopathy has been investigated using rac1 knockout mice. It was found 
that hyperglycaemia-induced up-regulation of NADPH oxidase activity, ROS production, cardiomyocyte 
apoptosis and myocardial dysfunction were all significantly reduced following cardiomyocyte-specific 
rac1 deletion30. In addition, treatment of hyperglycaemic db/db mice with a rac1 inhibitor inhibited 
NADPH oxidase activity, as expected, and also significantly reduced cardiomyocyte apoptosis30. 
Collectively, these data are consistent with rac1 playing a central role in NADPH oxidase-dependent 
ROS production that contributes to myocardial dysfunction in diabetes.  
 
2.2.2 Benefits of exercise training on NADPH oxidase-dependent oxidative stress  
Studies have been designed to determine whether exercise training affects the expression of 
NADPH oxidase regulatory subunits, and whether this modifies myocardial redox status. For example, 
induction of diabetes in rats using STZ treatment led to significantly increased left ventricular mRNA 
and protein expression of p47phox and p67phox31. The higher levels of these NADPH oxidase subunits 
in the left ventricle of the diabetic rats were significantly reduced when the rats underwent a three 
week treadmill endurance exercise protocol, such that expression was similar to that of non-diabetic 
rats undergoing the same exercise protocol. The findings of this study suggest a mechanism by which 
exercise training produces improved indices of cardiac function in diabetes, which have been reported 
previously32 and if these studies in rats are translatable to humans they provide support to the use of 
exercise training in diabetes to improve patient outcomes.  
 
2.3. Xanthine oxidase 
Xanthine oxidase, found in the cytosol of cardiomyocytes, produces H2O2 and O2. as by-
products of the metabolism of hypoxanthine and xanthine into uric acid10. The role of this enzyme in 
the pathogenesis of diabetic CVD is not well established, but it is important in the pathogenesis of non-
diabetic cardiac pathologies33.  Xanthine oxidase inhibitors have been used in both animal and human 
studies to develop a great understanding of the role of this enzyme in cardiovascular dysfunction, as 
summarised below.   
 
2.3.1. Animal studies with xanthine oxidase inhibitors  
The effect of the xanthine oxidase inhibitor allopurinol on cardiovascular dysfunction has been 
investigated using dogs in which dilated cardiomyopathy was induced, which led to a 4-fold increase 
in xanthine oxidase mRNA34. Allopurinol treatment resulted in significantly improved myocardial 
contractility and performance by augmenting the increased afterload on the heart, preventing the 
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reductions in cardiac contractility that are observed in heart failure34. In humans, cardiac uric acid 
accumulation, prior to its excretion in urine, may contribute to the pathophysiology of cardiomyopathy 
but dogs possess the enzyme urate oxidase that breaks down uric acid into allantoin. Therefore, it is 
clear that results of studies performed with mammalian models are not necessarily translatable to the 
human situation, and such data should be interpreted with caution. 
 
2.3.2. Human studies with xanthine oxidase inhibitors  
Elevated uric acid has been demonstrated as a biomarker for mortality and requirement for 
cardiac transplantation in heart failure patients35, so inhibition of xanthine oxidase may have beneficial 
outcomes in these individuals. A randomised double-blind placebo controlled trial using oxypurinol, 
the active metabolite of allopurinol, was conducted on patients with moderate to severe heart failure 
and it was found that only those patients with elevated baseline serum uric acid showed improvement 
with oxypurinol36. This suggests that inhibition of uric acid production has therapeutic potential in this 
subset of dilated cardiomyopathy patients, but further investigation is warranted to ascertain the 
precise mechanism(s) of action and therapeutic benefit of xanthine oxidase inhibitors in humans.  
 
2.4. 12/15 Lipoxygenase 
Lipoxygenases (LOX) are a family of enzymes that oxidatively metabolise arachidonic acid, a 
polyunsaturated fatty acid released from the plasma membrane following hydrolysis of 
phosphatidylcholine, into a variety of hydroperoxides. 12-LOX and 15-LOX convert arachidonic acid 
into 12- and 15-hydroxyeicosatetraenoic acids, releasing ROS in the process. Hyperglycaemia- induced 
activation of 12/15-LOX is associated with increased cardiac oxidative stress and diabetic 
cardiomyopathy10.  
The effects of 12/15-LOX on diabetic cardiomyopathy have been investigated using transgenic 
mice in which these enzymes have been deleted (12/15-LOX-KO) and which have been rendered 
diabetic through STZ treatment37. Immunofluorescence staining 4 weeks after the induction of 
diabetes illustrated upregulation of 12/15-LOX in the hearts of wild-type mice and these mice exhibited 
cardiac fibrosis. However, diabetic 12/15-LOX-KO mice exhibited reduced cardiac fibrosis than the 
wild-type mice, suggesting that disruption of the normal activity of 12/15-LOX is cardioprotective. In 
addition, levels of the lipid peroxidation by-product 4-HNE were significantly elevated in the 
myocardium of wild-type mice after STZ treatment but not in diabetic 12/15-LOX-KO mice37. These 
experiments therefore provide further supporting evidence of 12/15-LOX-derived oxidative stress in 
diabetic cardiomyopathy.  
Inhibition of 12-LOX has shown promising effects in preventing inflammation of human islets 
of Langerhans, thereby reducing inflammatory cytokine-induced beta-cell dysfunction and preserving 
glucose-stimulated insulin secretion38. This study suggests that 12-LOX inhibition may have therapeutic 
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potential to preserve functional mass of human islets but, as yet, no studies have investigated the 
effect of inhibition of this enzyme on diabetic CVD.  
 
2.5. Uncoupling of nitric oxide synthase 
The cardiovascular system synthesises NO through the activity of nitric oxide synthase (NOS), 
which exists in three isoforms: inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS 
(nNOS). Endothelial function in the cardiovascular system depends on the coupling of eNOS using the 
co-factor tetrahydrobiopterin (BH4). Physiological coupling of eNOS refers to the interaction of the 
eNOS haem group with L-arginine, the eNOS substrate, aided by BH4 during NO synthesis. BH4 is 
synthesised by GTP-cyclohydrolase-I (GTPCH) from guanosine triphosphate (GTP) de novo. Under 
oxidative stress, BH4 will be converted to 7,8-dihydrobiopterin (BH2), which can bind to eNOS, 
promote uncoupling and cause the synthesis of O2. instead of NO39 (Figure 5). This therefore leads to 
oxidative stress.  
 
 
2.5.1. The role of eNOS and iNOS in ROS generation     
It has been shown experimentally that up-regulation of eNOS protects against cardiac 
dysfunction. Thus, transgenic mice with a 30-fold increase in cardiomyocyte eNOS activity had 
improved LV function and reduced LVH following coronary artery ligation40. In contrast, iNOS may be 
involved in the pathogenesis of heart failure since cardiomyocyte-specific iNOS knockout mice were 
shown to have significantly increased survival following heart failure induced through myocardial 
infarction41. These mice also had reduced LV remodelling and demonstrated cardiomyocyte apoptosis. 
It has been reported that iNOS is up-regulated in the hearts of diabetic mice, which also had increased 
levels of 4-HNE and nitrotyrosine, a reactive nitrogen species42. A direct role for iNOS in the increased 
Figure 5. Uncoupling of endothelial nitric oxide synthase  
Physiological coupling of endothelial nitric oxide synthase (eNOS) requires its interaction with the 
cofactor tetrahydrobiopterin (BH4) to generate nitric oxide (NO). Under physiological conditions, 
BH4 is synthesised de novo by GTP-cyclohydrolase-I (GTPCH) from GTP. However, under oxidative 
stress, uncoupling of eNOS occurs: BH4 is converted to 7,8-dihydrobiopterin (BH2), which interacts 
with eNOS leading to the generation of superoxide (O2.) rather than NO, and this exacerbates the 
oxidative stress.  
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stress markers was demonstrated by attenuation of 4-HNE and nitrotyrosine following knockout of the 
iNOS gene42. These findings provide further evidence for the harmful, oxidative stress-inducing role of 
iNOS in diabetes. However, studies have also shown that a 40-fold increase in iNOS activity alone did 
not induce heart failure, indicating that increased iNOS activity per se does not trigger cardiac 
dysfunction43. 
 
2.5.2. The effect of increasing BH4 levels on ROS generation  
The importance of the BH4 synthesising enzyme GTPCH in normal cardiac function has been 
demonstrated in a recent study in which 4 weeks’ administration of 2,4-diamino-6-hydroxy-pyridine 
(DAHP), a GTPCH inhibitor, to C57BL/6 mice led to significant reduction in cardiac GTPCH activity that 
was accompanied by impaired function44. Of particular interest was the observation that transgenic 
mice overexpressing human GTPCH in their cardiomyocytes showed significantly attenuated diabetes-
induced cardiac remodelling and they had improved calcium handling44. While it is not possible, and 
not necessarily desirable, to overexpress GTPCH in humans, the observations of the association 
between reduced cardiac GTPCH activity and cardiac dysfunction suggest that maintaining activity of 
this enzyme in the heart may be a therapeutic option to improve cardiac function in diabetes. However, 
identifying the factors responsible for reductions in GTPCH activity in diabetes and selectively 
preventing this from occurring in the heart is unlikely to be therapeutically feasible, so a more 
practicable approach may be through elevating BH4 levels to compensate for the reductions in GTPCH. 
The efficacy of sepiapterin, a BH4 precursor downstream of GTPCH, on the generation of NOS-
derived oxidative stress in the diabetic mouse heart has been examined42. It was found that sepiapterin 
administration to diabetic mice significantly increased the concentration of cardiac BH4, inhibited 
production of stress markers stress such as 4-HNE and nitrotyrosine and improved cardiac 
performance. However, the iNOS knockout mice did not respond favourably to sepiapterin treatment, 
indicating that physiological coupling of iNOS using BH4, to promote NO synthesis and reduce ROS 
generation, is cardioprotective in diabetes42. These findings may explain why an earlier study did not 
observe heart failure in transgenic mice with increased iNOS activity43: it appears that it is enhanced 
generation of ROS via the uncoupling of iNOS that promotes cardiac dysfunction, rather than simply 
an increased expression or activation of the enzyme. A synthetic form of BH4 is well tolerated for 
treatment of the rare genetic condition phenylketonuria45, so BH4 replacement therapy may be 
possible for reducing diabetes-induced cardiovascular complications by promoting appropriate 
coupling of NOS enzymes and reducing oxidative stress.  
 
2.6. Signalling via the receptor for advanced glycation end-products (RAGE) 
Chronic hyperglycaemia leads to non-enzymatic covalent bonding of carbohydrates, such as 
glucose, to proteins and lipids in a process known as glycation. Glycation products that form in the 
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short-term can combine to form cross-linked structures known as advanced glycation end-products 
(AGEs). These modified proteins and lipids can bind to a cell surface receptor for AGE (RAGE) that is 
present on macrophages and endothelial cells and trigger a cascade of events through which ROS 
generation and activation of nuclear factor (NF)-κB leads to the production of pro-inflammatory 
cytokines (Figure 6). There is a vicious cycle in AGE signalling since NF-κB also up-regulates RAGE 
expression, leading to further ROS and cytokine synthesis. AGE/RAGE signalling is involved in the 
pathogenesis of both microvascular and macrovascular diabetic complications through the generation 
of oxidative stress.  
 
 
2.6.1. The role of RAGE in ROS generation  
It has been reported that concentrations of serum AGEs increase in healthy individuals with 
age, and these were associated with elevated levels of oxidative stress and inflammation46. Since 
chronic hyperglycaemia in uncontrolled diabetes increases AGE formation it follows that this will also 
lead to increased RAGE signalling, oxidative stress and inflammation, as outlined in Figure 4. Individuals 
with diabetic macrovascular complications have an 8-fold increase in RAGE mRNA expression 
compared to non-diabetic control patients and significantly higher serum AGE levels have been 
observed in diabetic patients with vascular complications47. This association of enhanced AGE 
concentrations with oxidative stress and diabetic complications suggests that measurements of serum 
AGE could be used clinically as a biomarker of vascular complications in diabetic patients.  
A recent study has shown that 16 weeks’ oral administration of mangiferin, an anti-
inflammatory and anti-diabetic agent, was able to significantly ameliorate the burden of the AGE/RAGE 
interaction in diabetic rats by reducing RAGE expression and the consequent activation of NF-κB in the 
myocardium and production of inflammatory cytokines48. The authors suggested that mangiferin 
treatment could be beneficial in diabetic cardiomyopathy through inhibiting ROS accumulation and 
Figure 6. Interaction of AGE proteins with RAGE 
Under conditions of hyperglycaemia enhanced glycation leads to the formation of cross-linked AGE 
proteins and lipids that bind to receptors (RAGE) to generate ROS, activate NF-κB and produce pro-
inflammatory cytokines such as IL-1 and TNF-α.  
Advanced glycation end-products (AGE); receptor for advanced glycation end-products (RAGE); 
reactive oxygen species (ROS); nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB); interleukin-1 (IL-1); tumour necrosis factor alpha (TNF-α).  
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the downstream damaging signalling events. Mangiferin supplementation for twelve weeks has been 
used successfully to improve serum lipid profiles in overweight individuals with hyperlipidaemia, 
without any adverse effects49. This approach may therefore be useful in treating diabetic 
cardiomyopathy through exerting systemic anti-inflammatory effects that could resolve over-activity 
of RAGE signalling in the heart and vasculature. However, there are currently no data available on the 
capacity of mangiferin to protect against cardiomyopathy in humans and it is clear that additional 
research is required in this area. 
 
2.6.2. Interaction between RAGE signalling and other ROS generating pathways  
As shown in Figure 4, AGE/RAGE cellular signalling leads to ROS generation and the activation 
of transcription factors, such as NF-κB. There is no consensus regarding the exact process by which 
ROS is generated through RAGE/AGE signalling, but evidence suggests that AGE binding to RAGE leads 
to activation of NADPH oxidase enzymes45,50 and formation of the MPTP51. It is hypothesised that 
AGE/RAGE-derived ROS can interact with NADPH oxidase enzymes to potentiate further ROS synthesis, 
and that NADPH oxidase-derived ROS can have the same effect on AGE/RAGE-derived ROS in a positive 
feedback loop45. Exposure of RAGE-expressing human endothelial cells to AGEs led to enhanced 
oxidative stress and expression of tissue factor, indicating the presence of inflammation50. 
Furthermore, gp91phox knockout mouse macrophages did not exhibit any increase in tissue factor or 
oxidative stress on exposure to AGE, providing direct evidence that NADPH oxidase is involved in the 
generation of ROS through AGE/RAGE signalling. These observations suggest an alternative activation 
pathway of NADPH oxidase, secondary to RAGE activation, and therefore another potential 
pharmacological target for macrovascular and microvascular complications of diabetes.  
In the hyperglycaemic state, increased glucose-derived NADH feeds into complex 1 of the ETC, 
and it has been observed that under these conditions of NADH excess AGE activation of RAGE elevates 
cytosolic ROS, which facilitates over-production of mitochondrial O2.51. These findings implicate ROS 
generation, caused by AGE/RAGE signalling in the hyperglycaemic state, as an upstream cause of 
mitochondrial ROS synthesis, indicating that pharmacological inhibition of this pathway may reduce 
oxidative stress and end-organ damage in uncontrolled diabetes. Given that AGE/RAGE signalling may 
act as a common upstream stimulus in ROS generating pathways, therapies targeting RAGE activation 
may be a sensible strategy for reducing oxidative stress to prevent or treat diabetic macrovascular 
complications. It should be noted that studies to date have mainly focused on the role of AGE/RAGE-
induced oxidative stress in the pathogenesis of renal diabetic complications. Further investigation into 
AGE/RAGE signalling in the diabetic heart is required to ascertain whether this is a pathway of 
significance in this type of diabetic insult, and whether treatment targeted at preventing AGE action 
will be of benefit in diabetic CVD.  
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2.7. Protein Kinase C-mediated signalling  
Protein kinase C (PKC) is a family of kinases that is involved in many cellular functions, including 
cell growth and death. Chronic activation of PKC under hyperglycaemic conditions leads to activation 
of a number of signalling cascades that can induce oxidative stress, including activation of NF-κB, 
increased activity of NADPH oxidases, overproduction of cytokines and induction of apoptosis, 
particularly in the vascular system. It is these alterations that have been linked to the pathogenesis of 
diabetic macrovascular disease.  
 
2.7.1. Diacylglycerol generation de novo 
Excessive production of O2. by the mitochondria under hyperglycemic conditions can inhibit 
the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which normally converts 
glyceraldehyde 3-phosphate into 1,3-diphosphoglycerate using nicotinamide adenine dinucleotide. 
When GAPDH is inhibited by O2., upstream glycolysis metabolites are forced into alternative pathways. 
In the case of PKC, glycerol 3-phosphate, derived from the glycolytic intermediate dihydroxyacetone 
phosphate, will be converted in a two-step process into DAG. Therefore, DAG levels are increased via 
this de novo synthesis pathway when glucose levels are elevated52 and this can lead to increased DAG 
concentrations in the heart53.  
It has been found that expression of the DAG-sensitive PKC isoforms, PKCβ1 and PKCβ2, are 
up-regulated in human heart failure cardiomyocytes54 and, consistent with this, PKCβ2 mRNA and 
protein expression in aortic endothelial and muscle cells were elevated in the hyperglycaemic state53.  
STZ-induced diabetes in transgenic mice over-expressing PKCβ2 in the myocardium (PKCβ2Tg) resulted 
in cardiac fibrosis that covered 2-3% of the left ventricle, while control mice had a total area of fibrosis 
of <0.1%55. Additionally, there was a 1.7-fold increase in collagen VI deposition in the ventricles of the 
diabetic PKCβ2Tg mice, which was completely alleviated by treatment with the PKCβ2 inhibitor55. 
These alterations in diabetic PKCβ2Tg mouse cardiac histology were thought to be a result of PKCβ2-
mediated cytokine production in the myocardium55, but as yet no causal relationship between PKC 
activation, cardiac hypertrophy and cytokine production has been established. Additional studies 
showed that PKC activation of in the mouse heart led to cardiac hypertrophy and dysfunction56 and 2 
to 10-fold increase in PKCβ2 mRNA in diabetic PKCβ2 transgenic mice correlated with LVH and reduced 
ventricular performance, while LY333531 significantly improved these parameters57. Overall, these 
studies support a role for PKC, in particular the PKCβ2 isoform, in mediating deleterious effects of 
hyperglycaemia on cardiac function.  
 
3. The damaging effects of oxidative stress on the cardiovascular system 
Increased phosphorylation of redox-sensitive kinases such as ERK1, ERK2 and JNK has been 
implicated in downstream signalling during oxidative stress. Significantly increased ERK1/2 
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phosphorylation has been identified in an animal model of LVH, and, as the LVH progressed, the level 
of ERK phosphorylation continued to increase27. These findings led to the proposal that the ROS 
generated in the myocardium acted via up-regulation of transcription factors that mediated the 
damaging effects. It is now well established that oxidative stress and PKC activation causes an increase 
in expression of NF-κB19, 37, 58, a transcription factor that increases iNOS expression, leading to increased 
NO production. NO can react with O2. to generate peroxynitrite, which is capable of inducing the 
formation of the MPTP and resulting in further ROS generation, cytochrome c leakage and apoptosis58. 
The generation of ROS specifically from the myocardium has been implicated in further mitochondrial 
dysfunction and modification of mitochondrial DNA21. Damage to mitochondrial DNA leads to impaired 
synthesis of mitochondrial proteins and promotes further ROS generation58.  
Oxidative stress can cause damage to RNA as well as DNA. Recently, a human trial discovered 
that type 2 diabetic patients with macrovascular complications had elevated urine concentrations of 
8-OH-dG, a marker of ROS-induced DNA damage (section 2.1.1), and levels of the RNA oxidation 
marker 8-OH-G were also significantly increased59. This study not only lends further support for 
oxidative damage to nucleic acids in diabetes, but introduces a potential new biomarker for untreated 
or undiagnosed diabetic complications which may have a clinical use in monitoring the progression of 
diabetic complications and their response to therapy.  
NF-κB activation also increases the expression of several pro-inflammatory, pro-fibrotic and 
pro-hypertrophic genes. Cardiac inflammation is an important part of the pathogenesis of CVD, and it 
is a strong candidate for the mediator of ROS-induced cardiac fibrosis and hypertrophy in diabetic CVD. 
Indeed, patients with type 2 diabetes have a 1.5-fold increased risk of LVH than non-diabetic controls60, 
and elevated concentrations of pro-inflammatory cytokines, such as IL-6 and TNF-α, have been 
recorded in patients with type 2 diabetes61. TNF-α caused enlargement of neonatal rat cardiomyocytes 
through increased generation of ROS, and this cardiac hypertrophy was abolished by administration of 
anti-oxidants62. Findings from further studies investigating the role of TNF-α in myocardial 
inflammation and fibrosis, specifically in diabetic cardiomyopathy, are consistent with this cytokine 
having a damaging effect on the heart. Thus, it has been found that treatment of diabetic rats with an 
anti-TNF-α antibody for six weeks reduced cardiac TNF-α expression by 2-fold, and this was 
accompanied by reductions both in cardiac IL-1 expression and ERK phosphorylation63. Inhibition of 
TNF-α in the diabetic rats was also associated with significant reductions in collagen deposition and 
improved LV function, indicating that TNF-α antagonism may have a role in diabetic cardiomyopathy 
therapy.  
Oxidative stress in the diabetic myocardium is also associated with increased levels of 4-HNE 
(section 2.1.1). Administration of the anti-oxidant N-acetyl-cysteine abolished the elevation of 4-HNE 
and reduced expression of TNF-α and NF-κB, producing a concomitant reduction in collagen 
deposition, and therefore fibrosis37. This highlights that inflammation and fibrosis in diabetic 
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cardiomyopathy is caused, at least in part, by oxidative stress and illustrates the potential clinical use 
of anti-oxidants against diabetic cardiomyopathy.  
 
4. Therapeutic potential of anti-oxidants in diabetic cardiomyopathy   
The human body synthesises anti-oxidant enzymes to maintain the balance between ROS 
generation and degradation and while ROS play physiological functions under normal conditions it is 
generally accepted that excess ROS is harmful, as summarised above. A recent study has demonstrated 
that levels of the anti-oxidant glutathione peroxidase 3 are reduced with age, accompanied by an 
increased risk of adverse cardiovascular events64 suggesting that preventing this decline or provision 
of exogenous anti-oxidants may be therapeutically beneficial. Several studies have investigated anti-
oxidants as therapies for diabetic complications. Some of those that are relevant to protection against 
diabetic cardiomyopathy are summarised below, with their sites of action shown in Figure 7, and 
section 4.9 considers the therapeutic feasibility of these anti-oxidants.  
 
4.1. Coenzyme-Q10 
Coenzyme-Q10 is an endogenously synthesised anti-oxidant and a component of the 
mitochondrial ETC. Highly metabolic tissues such as the myocardium are abundant in mitochondria 
and therefore have high concentrations of coenzyme-Q10. A study in the hyperglycaemic db/db mouse 
model has led to the proposal that coenzyme-Q10 may be as effective as current therapies for diabetic 
cardiomyopathy given that its administration was associated with similar reductions in LV mass and 
collagen deposition to those obtained with the ACE inhibitor ramipril65. These observations in mice 
appear promising, but further investigations are required to determine whether exogenous provision 
of coenzyme-Q10 has beneficial effects to ameliorate cardiomyopathy in humans. Coenzyme-Q10 is 
currently available as a non-prescription oral dietary supplement, and a recent randomised controlled 
trial indicated that its use as an adjunct therapy for chronic heart failure was associated with a 
significant reduction in major adverse cardiovascular events66. There is currently no information on the 
utility of coenzyme Q-10 as a stand-alone therapy for heart failure, nor whether it is suitable for 
patients with diabetic cardiomyopathy. 
 
4.2. Mito-TEMPO 
The mitochondria-targeted anti-oxidant mito-TEMPO has been investigated as a potential 
treatment for diabetic cardiomyopathy in mice67. It was found that H2O2 generation was elevated in 
hyperglycaemic db/db mice and in mice that had been made diabetic by STZ administration, and daily 
injection of mito-TEMPO significantly reduced the hyperglycaemia-induced elevation in H2O2. In 
addition, mito-TEMPO administration in vitro protected against hyperglycaemia-induced 
cardiomyocyte death. Thus, this study is consistent with mito-TEMPO reducing cardiomyopathic 
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changes in the hyperglycaemic state in both type 1 and type 2 diabetic mouse models. Mito-TEMPO is 
targeted to the mitochondria, but it was also observed that it reduced mRNA expression of gp91phox 
and p47phox, components of NADPH oxidase (Figure 4). The findings from this study therefore provide 
further support of an interaction between NADPH oxidase and the mitochondria in the generation of 
ROS.  
 
4.3 Peroxiredoxin-3  
Peroxiredoxin-3 (Prx-3) is another mitochondrial anti-oxidant, which has recently been 
investigated in the context of hyperglycaemia-induced cardiac dysfunction in diabetic 
cardiomyopathy68. It was found that Prx-3 levels were significantly reduced in rat H9c2 cardiac cells 
maintained under hyperglycaemic conditions, and also in STZ-induced diabetic rats. The induction of 
diabetes in these rats led to increased cardiac 4-HNE, which was used as a marker of lipid peroxidation. 
Treatment of the diabetic rats with the naturally occurring flavonol quercetin resulted in elevation of 
endogenous Prx-3 such that normal Prx-3 levels in the myocardium were restored and cardiac troponin 
I levels were also increased, indicating alleviation of cardiac injury and improved cardiac function. 
Quercetin treatment also reduced 4-HNE levels towards normal and diabetes-induced remodelling of 
the heart, as determined by myocardial fibrosis, altered cardiac architecture and hypertrophic markers 
such as connective tissue growth factor, was attenuated with quercetin treatment. Overall, the data 
presented in this study indicate that increasing endogenous Prx-3 through administration of quercetin 
is cardioprotective, at least in rodents, but the therapeutic potential of this approach for treatment of 
cardiomyopathy in humans has not yet been investigated.  
 
4.4 Rutin 
Rutin, a glycoside of quercetin, exhibits anti-oxidant and anti-inflammatory properties. Its anti-
inflammatory effects have been demonstrated in a recent study in which its intraperitoneal 
administration in a rat model of neuroinflammation significantly reduced expression of the 
inflammatory cytokines IL-1β, IL-6 and TNF-α, and it also diminished RAGE and NF-κB protein 
expression69. The effect of rutin to protect against diabetic cardiomyopathy has also been investigated, 
and it has been found that its administration to STZ-induced diabetic rats for 24 weeks resulted in 
reductions both in cardiac oxidative stress and cardiac inflammation70. The study also demonstrated 
that the total anti-oxidant capacity of the rutin-treated diabetic rats was significantly improved and 
their TNF-α expression was dramatically reduced. Additionally, histopathological observations of the 
hearts of the diabetic animals that had been treated with rutin established improved indices of cardiac 
hypertrophy. These findings in rats suggest a potential role for the anti-oxidant rutin in the 
pharmacological treatment of diabetic cardiomyopathy.   
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4.5 N-acetyl-L-cysteine 
The glutathione precursor anti-oxidant N-acetylcysteine (NAC) has free radical scavenging 
properties and it has been reported that treatment of rat cardiomyocytes with NAC abolished TNF-α-
induced ROS generation71. In vivo protective effects of NAC in diabetic cardiomyopathy have also been 
demonstrated. Thus, NAC administration after STZ-induced diabetes in mice led to significant 
attenuation of the cardiac fibrosis that had been caused by the diabetes, which was associated with a 
marked reduction in ROS formation72. The study highlighted that better cardiac outcomes were 
obtained when NAC was administered early after the induction of diabetes by STZ, indicating that 
timely therapeutic intervention is likely to be important in preventing long term cardiac damage that 
occurs with sustained hyperglycaemia. 
NAC may also have beneficial effects through reducing NADPH oxidase activity, as has been 
reported for Mito-TEMPO (section 4.2), since diabetes-induced up-regulation of p22phox, a crucial 
subunit of NADPH oxidase, was reduced in diabetic rats treated with NAC73. In the same study it was 
demonstrated that NAC-treated diabetic rat myocardium had significantly lower indices of oxidative 
stress. These results are consistent with NAC treatment conferring a reduced capability of the 
myocardium to generate ROS through the activity of NADPH oxidase and suggest that therapeutic 
treatment of diabetic cardiomyopathy with NAC may be of benefit by reducing cardiac oxidative stress 
and cardiac fibrosis, potentially by affecting the synthesis of NADPH oxidase subunits.  
 
4.6 Sitagliptin  
Sitagliptin is currently in clinical use as a diabetes therapy. It inhibits dipeptidyl peptidase-4 
(DPP-4), the enzyme responsible for inactivating the incretin hormone glucagon-like peptide-1 (GLP-
1), and sitagliptin is reported to be cardioprotective in a rat model with type 2 diabetes through 
maintaining endogenous GLP-1 levels74. More recently, it has become apparent that sitagliptin can 
protect against diabetic cardiomyopathy by down-regulating the JAK/STAT (Janus kinase/signal 
transducer and activator of transcription) pathway, which can cause cardiac hypertrophy through 
increased cell differentiation, growth, survival and angiogenesis75. It has recently been demonstrated 
that daily administration of sitagliptin via oral gavage to STZ-induced diabetic rats for 90 days led to a 
significantly reduced heart-to-body weight ratio, indicating reduced levels of cardiac hypertrophy76. In 
addition, sitagliptin administration to the diabetic rats caused marked improvement in activities of the 
anti-oxidant enzymes superoxide dismutase and catalase. Furthermore, cardiac homogenates of the 
sitagliptin-treated diabetic rats showed significantly reduced levels of lipid peroxidation and reduced 
myocardial cell degeneration and collagen deposition through attenuation of cardiac IL-6 levels. 
Immunochemical staining demonstrated that sitagliptin reduced phosphorylation of JAK2 and STAT3 
in the diabetic rat heart. These findings indicate that sitagliptin can have cardioprotective effects in rat 
models of diabetes by impairing signalling through the JAK/STAT pathway. It was not investigated in 
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the study whether the reduced JAK/STAT phosorylation was secondary to elevations in GLP-1, but the 
observed reduction in IL-6 suggests inhibition of RAGE cascades, and it has been reported previously 
that sitagliptin impairs RAGE signalling77. There are no reports of use of DPP-4 inhibitors such as 
sitagliptin being associated with reductions in cardiac hypertrophy in humans, and further studies are 
required to determine whether they may have a role in the prevention or treatment of diabetic 
cardiomyopathy.  
 
4.7 Nobiletin  
Nobiletin is a citrus flavonoid that is reported to reduce the depletion of endogenous anti-
oxidants such as glutathione, superoxide dismutase and catalase in rats in which acute renal injury was 
induced by administration of the oxidative stress-generating anti-cancer drug cisplatin78. Recent 
investigation into the therapeutic effects of nobiletin has indicated a potential role for this drug in 
diabetic cardiomyopathy. Thus, administration of nobiletin for 11 weeks to STZ-induced diabetic mice 
with cardiomyopathy led to improved LV function79. In addition, analysis of mRNA expression of 
NADPH oxidase subunits in cardiac tissue showed that nobiletin-treated diabetic mice had significant 
reductions in p22phox and gp91phox compared to the control diabetic mice, which may account for 
the lower levels of the lipid peroxidation marker malondialdehyde (MDA) with nobiletin 
administration. Additional exploration of the cellular mode of action of nobiletin showed that it 
significantly attenuated the diabetes-induced increases in TNF-α and IL-6 mRNA in the myocardium 
through reduced activation of NF-κB. These findings indicate that nobiletin may be able to abate 
oxidative damage in the diabetic myocardium by reducing hyperglycaemia-induced NADPH oxidase 
up-regulation, preventing excessive ROS accumulation and therefore impeding NF-κB activation and 
synthesis of pro-inflammatory cytokines.  
 
4.8 Curcumin  
 Curcumin, isolated from turmeric powder, has known anti-oxidant, free radical scavenging and 
anti-inflammatory effects80. In a study in which curcumin was administered for 16 weeks to diabetic 
rats it was found that the indices of LV systolic function were markedly improved and cardiomyocyte 
hypertrophy was significantly alleviated81. The diabetes-induced increases in AGE accumulation and 
RAGE expression were attenuated with curcumin treatment and curcumin also protected against the 
increases in cardiac protein expression of p47phox and gp91phox. Measurements of MDA and 
superoxide dismutase activity indicated that curcumin therapy led to an overall reduction in oxidative 
stress. These findings are suggestive of multiple sites of beneficial action of curcumin: through action 
on AGE, RAGE and NADPH oxidase, supporting a therapeutic role for this anti-oxidant in diabetic 
cardiomyopathy. A recent meta-analysis of eight randomised controlled trials indicated that curcumin 
supplementation led to a significant reduction in circulating concentrations of the pro-inflammatory 
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cytokine TNF, and the authors proposed that curcumin could be a cost-effective therapy for TNF-
associated diseases82.  
 
 
 
4.9. Feasibility of therapeutic use of anti-oxidants for diabetic cardiomyopathy  
 The studies described above are generally supportive of the use of anti-oxidant therapies for 
diabetic cardiomyopathy, but they have been carried out in animal models in which a type 1 diabetic 
phenotype has been generated by STZ-induced beta-cell destruction or in the insulin resistant db/db 
mouse model of type 2 diabetes. It is not yet clear whether these rodent studies may be directly 
translated to the human situation, and consideration must be made of the potential for harmful long 
term effects such as increased risk of cancer83 or higher mortality84 that may occur with systemic 
administration of anti-oxidants. Targeting the heart through administration of therapeutically selective 
anti-oxidants is an attractive option, but there is no evidence of the existence of cardiac-specific 
molecules in the signalling cascades that promote the deleterious effects of oxidative stress and this is, at 
best, a remote future possibility. Nonetheless, well-tolerated systemic anti-oxidants such as curcumin, 
which have multiple beneficial effects and are well tolerated, may prove to be useful in reducing 
oxidative stress in diabetic cardiomyopathy. 
The applicability of these anti-oxidants for treatment of human diabetic cardiomyopathy can 
be gauged, to a certain extent, by considering data obtained from meta-analyses of randomised 
controlled trials where some of these agents have been used for other conditions. Thus, there is 
Figure 7. Sites of action of anti-oxidants  
A variety of anti-oxidants have been tested in animal models of diabetic cardiomyopathy, and the 
figure summarises how they interact with the O2. generating pathways to protect against cardiac 
dysfunction. 
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evidence that curcumin supplementation in humans can decrease circulating TNF82 and that 
quercetin can reduce blood pressure85. However, Cochrane reviews investigating other anti-oxidant 
therapies such as coenzyme Q10 for chronic heart failure66 and hypertension86, have given conflicting 
outcomes with suggestions of positive effects66 or that its use is not associated with a clinically significant 
beneficial outcome86. This suggests that anti-oxidants are not generalised panaceas and that they may lead 
to improvements in some, but not all clinical conditions associated with oxidative stress. Furthermore, in 
some cases anti-oxidant use has been associated with harmful outcomes. For example, NAC 
administration for systemic inflammatory response syndrome (SIRS) and sepsis led to cardiovascular 
depression if it was given later than 24 hours after onset of symptoms87. However, it should be noted 
that in the trials evaluating the effectiveness of NAC for treating SIRS and sepsis it was delivered by 
intravenous infusion, while it was administered orally in mice where its effects on cardiac fibrosis were 
investigated71,72. 
 It is also worth considering whether using anti-oxidants to combat increased oxidative stress in 
diabetes is the best strategy to treat diabetic cardiomyopathy. As stated in section 1.3, generation of ROS 
is an appropriate cellular response to maintain homeostatic balance and blocking this through the use of 
anti-oxidants could be deleterious. For example, in a study investigating the progression of 
atherosclerosis in diabetic mice it was demonstrated that although deletion of the NADPH oxidase 
isoform NOX4 led to a reduction in the ROS generating capacity of the mice there was actually an 
increase in atherosclerosis88. This therefore suggests that NOX4-derived ROS are protective against 
diabetic atherosclerosis, consistent with observations that NOX4 deletion led to increased apoptosis88 
and NOX4 overexpression improved endothelial function89. Thus, these studies challenge the 
traditional consensus of oxidative stress and an imbalance in cellular redox states leading to cell 
dysfunction through lipid, protein and DNA modification and support a new paradigm where ROS 
generated by the NOX4 isoform may protect against onset of disease. It is therefore clear that a more 
nuanced approach to anti-oxidant therapy for the treatment of diabetic cardiovascular disease is 
required, rather than a global “one size fits all” strategy.  
 
5. Conclusions and future perspectives  
Uncontrolled diabetes produces a chronic hyperglycaemic state that is associated with 
potentially fatal myocardial tissue damage. There have been thorough investigations on 
hyperglycaemia-induced generation of oxidative stress in diabetic CVD, and the consensus is that there 
is indeed an alteration in the oxidative state of the diabetic heart. Hyperglycaemia provokes the 
myocardium into excessive ROS production through a number of inter-related pathways, with research 
suggesting that the interaction between AGEs and RAGE is a common upstream pathway. Oxidative 
stress is highly damaging: it causes modification of lipids, proteins, DNA and it activates transcription 
factors that drive inflammation, fibrosis and hypertrophy. As such, therapeutic interventions to 
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decrease oxidative stress could, in theory, protect against hyperglycaemia-induced myocardial tissue 
damage. However, while the research presented here regarding the use of anti-oxidants, mainly in 
animal models of diabetes, appears promising, there is still insufficient information available on the 
significance of the sources of oxidative stress in different tissues or on the potential benefits and risks 
of systemically reducing oxidative stress in the diabetic state in humans. Further study into the 
integrated mechanisms that generate ROS in the diabetic heart and effectors that are responsible for 
the deleterious effects will provide greater insight into the pathogenesis of diabetic CVD and, 
potentially, lead to introduction of targeted therapies for this potentially fatal condition.  
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